Brainomix

Brainomix is a medical software company specializing in the development of AI-powered imaging biomarkers for precision medicine. They are based in Oxford, UK, and have offices in Dublin and Chicago. The company was founded in 2010 as a spin-out from the University of Oxford and has been a pioneer in the field of medical AI imaging. Brainomix's flagship product, e-Stroke Suite, is a comprehensive stroke imaging solution designed to help clinicians interpret images and make faster, more confident treatment decisions for patients with suspected stroke.

Brainomix is continuing to expand beyond stroke into new areas, including interstitial lung disease (ILD) and cancer. Their technology is being used in clinical trials and is helping to improve the accuracy and efficiency of disease diagnosis and treatment. Brainomix is committed to developing innovative AI solutions that improve patient outcomes and is backed by leading healthtech investors, including Boehringer Ingelheim Venture Fund, Parkwalk, and Tencent Holdings.

Brainomix is a medical software company specializing in AI-powered imaging biomarkers. They are committed to developing innovative solutions that enable precision medicine and improve treatment decisions, ultimately leading to better patient outcomes. Their technology automates validated imaging biomarkers for a variety of conditions, including stroke, Interstitial Lung Disease (ILD), and cancer, with the goal of providing fast, accurate, and objective assessments to support clinicians in making informed decisions.

Brainomix promotes a culture of innovation, collaboration, and patient-centricity. The company's emphasis on scientific excellence and world-class expertise is reflected in its team of clinicians, scientists, and engineers who are passionate about using AI to improve patient outcomes. Brainomix fosters a collaborative environment where employees can share ideas and work together to develop innovative solutions that drive progress in the healthcare industry. This culture is further evident in their commitment to forming value-generating partnerships with leading healthtech investors and Life Sciences companies.